Insider Selling: BioLife Solutions Inc (BLFS) CFO Sells 10,000 Shares of Stock

BioLife Solutions Inc (NASDAQ:BLFS) CFO Greef Roderick De sold 10,000 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $16.76, for a total value of $167,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,359 shares in the company, valued at approximately $676,416.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Greef Roderick De also recently made the following trade(s):

  • On Wednesday, April 17th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $16.53, for a total value of $165,300.00.
  • On Wednesday, March 20th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $19.83, for a total value of $198,300.00.
  • On Wednesday, February 20th, Greef Roderick De sold 10,000 shares of BioLife Solutions stock. The shares were sold at an average price of $17.23, for a total value of $172,300.00.

Shares of BLFS stock traded up $0.48 during mid-day trading on Friday, hitting $18.22. 129,500 shares of the stock were exchanged, compared to its average volume of 159,005. The firm has a market cap of $336.52 million, a price-to-earnings ratio of 128.64 and a beta of 1.53. BioLife Solutions Inc has a 12-month low of $8.50 and a 12-month high of $26.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. As a group, research analysts predict that BioLife Solutions Inc will post 0.13 EPS for the current year.

Several equities analysts recently commented on BLFS shares. ValuEngine raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Thursday, January 31st. BidaskClub raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Zacks Investment Research lowered BioLife Solutions from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. BioLife Solutions has a consensus rating of “Buy” and a consensus price target of $18.20.

Hedge funds have recently modified their holdings of the business. Roubaix Capital LLC purchased a new position in shares of BioLife Solutions during the first quarter worth about $809,000. Vanguard Group Inc. grew its holdings in shares of BioLife Solutions by 43.1% during the third quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of BioLife Solutions by 43.1% during the third quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock worth $7,839,000 after purchasing an additional 134,869 shares during the last quarter. BlackRock Inc. grew its holdings in shares of BioLife Solutions by 199.8% during the third quarter. BlackRock Inc. now owns 153,610 shares of the medical equipment provider’s stock worth $2,688,000 after purchasing an additional 102,364 shares during the last quarter. Finally, GSA Capital Partners LLP grew its holdings in shares of BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 2,400 shares during the last quarter. 41.21% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.thelincolnianonline.com/2019/05/17/insider-selling-biolife-solutions-inc-blfs-cfo-sells-10000-shares-of-stock.html.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: Outstanding Shares and The Effect on Share Price

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.